Whole-body diffusion-weighted MRI has recently gained a lot of attention as a promising technique for the assessment of multifocal bone disease such as multiple myeloma and bone metastases from breast and prostate cancer [1–3]. Compared to other imaging techniques, diffusion-weighted MRI has a high sensitivity and specificity for disease detection, without exposing the patient to ionizing radiation. Uniquely, diffusion imaging also enables therapy response to be evaluated, with particular application for bone disease. However, one challenge is the relatively large effort in response interpretation, due to the number of images that are generated and the lack of tools for efficient evaluation for multifocal disease.

This limitation was addressed by an efficient analysis approach that has been proposed by Blackledge et al. [4], using a threshold-based segmentation on diffusion-weighted images to identify regions of disease. Based on this segmentation, the overall tumor volume as well as histogram metrics of the corresponding apparent diffusion coefficient (ADC) maps are analyzed. Excellent inter- and intra-observer agreement of this computed approach was demonstrated recently in a pilot study [5].

Figure 1: Application workflow. A computed high b-value image ($b = 800 \, \text{s/mm}^2$) serves as input. An initial segmentation of the multiple myeloma lesions is obtained by thresholding and then edited to manually exclude regions from the analysis. In this case the brain, neck nodes, salivary glands, kidneys, spleen, and pelvic bowel were removed. Furthermore, the lower lumbar spine was removed, because of artifacts from a spine stabilization. Finally, back-mapping analysis reveals the ADC associated with each voxel, and provides detailed ADC histogram metrics (see also Figure 2).
Figure 2: Example result for a multiple myeloma patient before and after one cycle of ESHAP (etoposide, methylprednisolone, cytarabine and cisplatin) therapy. The ADC back-mapping (2A) indicates reduced tumor burden and region based responses by yellow and green overlays. The ADC histograms (2B) show a significant change due to the treatment. The ADC statistics show reduced active tumor volume, increased mean and median ADC, and decreased ADC skewness and kurtosis. While 94.5% of the segmented volume were in the ADC range associated with active tumor at baseline, only 13.8% of the volume at follow-up were in the same range (ADC < 1000 µm²/s). Conversely, the fraction of the data in the ADC range associated with tumor cell kill (ADC > 1500 µm²/s) has increased from 0.9% at baseline to 44.7% on the follow-up study.

Quantitative whole-body diffusion MRI is implemented in the syngo via Frontier MR Total Tumor Load\(^1\) released research prototype: It uses diffusion-weighted images as input and allows creation of a 3D mask on diffusion images, for the analysis of the corresponding ADC maps. The prototype supports evaluation of up to two time-points, side-by-side and utilizes maximum intensity projections (MIPs) to facilitate efficient visual assessment of the intermediate result at each step. The workflow is structured in three steps, as depicted in Figure 1. The example illustrates the processing steps for a patient with multiple myeloma:

1. **Initial segmentation**: An initial mask is defined interactively by applying a threshold to a computed high b-value image (for example, \(b = 800\ s/mm^2\)). An automatic outlier removal can be performed to reduce false positive voxels due to artifacts or T2 shine-through.

2. **Mask editing**: The initial mask is edited by the user. The user can perform volume punching in order to exclude artifact regions and normal hyperintense organs such as brain, kidneys, spleen, testes, salivary glands etc, or users can choose to retain only a selected volume of interest. Furthermore, a volumetric, semi-automatic segmentation tool is available for manually adding false negative regions to the mask if not already captured.

<table>
<thead>
<tr>
<th>Metric</th>
<th>Baseline</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume ([cm^3])</td>
<td>1298</td>
<td>978</td>
</tr>
<tr>
<td>ADC mean ([\mu m^2/s])</td>
<td>653</td>
<td>1432</td>
</tr>
<tr>
<td>ADC median ([\mu m^2/s])</td>
<td>609</td>
<td>1437</td>
</tr>
<tr>
<td>ADC skewness</td>
<td>2.11</td>
<td>0.12</td>
</tr>
<tr>
<td>ADC e. kurtosis</td>
<td>8.21</td>
<td>0.07</td>
</tr>
<tr>
<td>% Low</td>
<td>94.5</td>
<td>13.8</td>
</tr>
<tr>
<td>% High</td>
<td>0.9</td>
<td>44.7</td>
</tr>
</tbody>
</table>

\(^{1}\text{syngo via Frontier is for research only, not a medical device.}\)

Table 1: Segmentation statistics. The tumor volume as well as several histogram metrics have changed significantly during treatment.
3. **Analysis:** The ADC histogram and corresponding statistics are computed for the edited masked volume. Histogram metrics include mask volume, mean, median, standard deviation, skewness, excess kurtosis, and customizable percentiles.

Regions of low, intermediate and high ADC values can be inspected interactively by adjusting slider positions on the histogram. Depending on the ADC chosen, the colored back-mapping ADC overlays allow the visual discrimination of regions with untreated disease (typically associated with lower ADC values) compared to disease regions that have been treated effectively (high ADC values).

In the example shown in Figure 2, the 95th percentile of the baseline examination, approximately 1000 µm²/s, was used as lower ADC threshold and 1500 µm²/s was used as upper threshold. The ADC back-mapping in Figure 2A shows a red overlay for voxels with an ADC below 1000 µm²/s, a yellow overlay for voxels in the intermediate range, and a green overlay for voxels above 1500 µm²/s. The corresponding histograms and limits are shown in Figure 2B. The patient shows changes consistent with a significant response to the therapy, indicated by the emergence of mixed yellow and green regions in the humeri, pelvis, and femur. However, red regions continue to be seen indicating the continued presence of untreated disease.

The histogram statistics, listed in Table 1, show a reduction of the total diffusion volume, from 1298 cm³ at baseline to 978 cm³ at follow-up, and a radical change in the histogram shape. The mean and median values have increased from 653 (609) µm²/s at baseline to 1432 (1437) µm²/s in the follow-up examination. The skewness decreased from 6.53 to 1.44, while the excess kurtosis decreased from 9.78 cm³ at follow-up, and a radical change in the histogram shape. The mean and median values have increased from 653 (609) µm²/s at baseline to 1432 (1437) µm²/s in the follow-up examination. The skewness decreased from 2.11 to 0.12, while the excess kurtosis decreased from 8.21 to 0.07.

Further examples obtained with the syngo.via Frontier MR Total Tumor Load released research prototype software can be found in the article “Metastatic Prostate Cancer in Practice – the MET-RADS-P Imaging Response System Using Whole-body MRI” on page 64 and in the case study “Observing Endocrine Therapy Resistance in Metastatic Breast Cancer with Whole-body MRI” on page 80 of this issue of MAGNETOM Flash.

To summarize, the syngo.via Frontier MR Total Tumor Load released research prototype provides an efficient and reproducible workflow with quantitative results for the processing and analysis of whole-body diffusion-weighted images in the response assessment setting. It is a promising tool to support the standardization of whole-body MRI for treatment response monitoring of bone disease in particular. Extensions like a fully automatic bone segmentation (as described in “Whole-body MRI Reading and Bone Assessment with syngo.via Frontier MR Bone Scan” on page 76 in this issue), simultaneous consideration of other MR parameters such as the normalized signal intensity, fat fraction, or Gadolinium enhancement fraction [6, 7], and integrated classification techniques to detect and separate regions of discordant response [7], may further add to the potential of the technique to promote high-precision medicine.

**References**

3. Padhani AR and Tunariu N, Metastatic response system in using whole body MRI for prostate cancer in practice. See also page 76 in this issue of MAGNETOM Flash.

**Contact**

Robert Grimm, Ph.D.
Siemens Healthcare GmbH
HC DI MR PI TIO ONCO
Postbox 32 60
91050 Erlangen
Germany
Phone: +49 (0) 9131 84-2717
robertgrimm@siemens.com

Reprinted from MAGNETOM Flash (68) 2/2017